Virtual Patients: Is Allergen Immunotherapy the Right Choice for Your Patient?

In these patient simulations, you will assess the appropriateness of allergen immunotherapy (AIT) for patients with particular health characteristics. Using evidence from the literature, you will determine if it is likely that immunotherapy will be safe and effective in various clinical scenarios. In some cases, you may need to help your patients gain control of other symptoms before starting AIT. You will differentiate the appropriateness of subcutaneous versus sublingual immunotherapy (SCIT versus SLIT) based on patient’s clinical characteristics and test results, and in patients who are not appropriate candidates for immunotherapy, you will have the opportunity to prescribe alternative treatment.

Making IT Count is funded through an educational grant from Merck & Co., Inc.

Target Audience

  • Allergist/immunologists
  • Fellows-in-Training
  • Allied Health Professionals

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Select patients for immunotherapy based on clinical presentation, co-morbid medical conditions and other patient-specific considerations, and allergy skin test findings in accordance with best practices covered in the literature
  • Determine whether SCIT or SLIT is most appropriate based on patient characteristics and test results
  • Develop strategies to decrease the risk of adverse outcomes if SCIT or SLIT is given to patients for whom safety concerns may be present
Available credit: 
  • 0.75 Attendance
    Attendance credit.
  • 0.75 CE
    CE credit.
  • 0.75 CME
    CME credit.
Course opens: 
Course expires: 

Content Authors
TTolly Epstein, MD FAAAIolly Epstein, MD FAAAAI
University of Cincinnati School of Medicine and Allergy Partners of Central Indiana, Indianapolis, IN
Relevant relationships: None

PPeter S. Creticos, MD FAAAAIeter S. Creticos, MD FAAAAI
Creticos Research Group & Clinical Practice, Crownsville, MD
Relevant relationships: ASIT, Circassia, Allergy Therapeutics, Greer, Benevolent: Consultant

CME Committee Reviewers
Maria Crain, RN MA CPNP
Children’s Medical Center Dallas, Dallas, TX
Relevant relationships: None

Karen L. Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic/Georgetown University School of Nursing, Oklahoma City, OK
Relevant relationships: MEDA, Novartis: Speaker

Thomas P. Miller, MD FAAAAI
Allergy Associates of Western Michigan, Grandville, MI
Relevant relationships: Teva Mylan

AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

  • Employment. Name of employer and job title.
  • Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
  • Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
  • Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
  • Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
  • Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
  • Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.


Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 0.75 Contact Hours.

Medium and Method of Physician Participation 
Follow these steps to complete the activity:

  1. Register for the activity.
  2. Review the CME Info and Disclosure information.
  3. Complete all required components.
  4. Complete the Commitment to Change form.
  5. Complete the activity evaluation.
  6. Claim your credits. Enter only the number of credits earned based on your participation in the activity.
  7. Print or save your certificate.

AAAAI Privacy Policy
To verify your participation in live educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at

Release date
Original release date: February 12, 2018. Valid for credit through February 11, 2020.

Available Credit

  • 0.75 Attendance
    Attendance credit.
  • 0.75 CE
    CE credit.
  • 0.75 CME
    CME credit.


Please login or register to take this course.

Required Hardware/software

This course content will not work in Internet Explorer (IE). Please download one of the following (free) browsers to view and complete this course:

  • Google Chrome
  • Mozilla Firefox

Pop-ups must be enabled in order to access all course content.